Introduction ▼
In psychiatry, around 130 drugs are now available which have been detected and developed during the last 60 years [ 54 ] . These drugs are eff ective and essential for the treatment of many psychiatric disorders and symptoms. Despite enormous medical and economic benefi ts, however, therapeutic outcomes are still far from satis factory for many patients [ 5 , 6 , 396 , 661 ] . Therefore, after having focused clinical research on the development of new drugs during more Therapeutic drug monitoring (TDM), i. e., the quantifi cation of serum or plasma concentrations of medications for dose optimization, has proven a valuable tool for the patient-matched psychopharmacotherapy. Uncertain drug adherence, suboptimal tolerability, non-response at therapeutic doses, or pharmacokinetic drug-drug interactions are typical situations when measurement of medication concentrations is helpful. Patient populations that may predominantly benefi t from TDM in psychiatry are children, pregnant women, elderly patients, individuals with intelligence disabilities, forensic patients, patients with known or suspected genetically determined pharmacokinetic abnormalities or individuals with pharmacokinetically relevant comorbidities. However, the potential benefi ts of TDM for optimization of pharmacotherapy can only be obtained if the method is adequately integrated into the clinical treatment process. To promote an appropriate use of TDM, the TDM expert group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued guidelines for TDM in psychiatry in 2004. Since then, knowledge has advanced signifi cantly, and new psychopharma-cologic agents have been introduced that are also candidates for TDM. Therefore the TDM consensus guidelines were updated and extended to 128 neuropsychiatric drugs. 4 levels of recommendation for using TDM were defi ned ranging from "strongly recommended" to "potentially useful". Evidence-based "therapeutic reference ranges" and "dose related reference ranges" were elaborated after an extensive literature search and a structured internal review process. A "laboratory alert level" was introduced, i. e., a plasma level at or above which the laboratory should immediately inform the treating physician. Supportive information such as cytochrome P450 substrateand inhibitor properties of medications, normal ranges of ratios of concentrations of drug metabolite to parent drug and recommendations for the interpretative services are given. Recommendations when to combine TDM with pharmacogenetic tests are also provided. Following the guidelines will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems. Thereby, one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data so that, ultimately, the patient can profi t from such a joint eff ort.
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considerable interindividual variability in the pharmacokinetic properties of the patient [ 524 , 526 ] . At the very same dose, a more than 20-fold interindividual variation in the medication's steady state concentration in the body may result, as patients diff er in their ability to absorb, distribute, metabolize and excrete drugs due to concurrent disease, age, concomitant medication or genetic peculiarities [ 61 , 94 , 310 , 311 , 334 , 335 , 374 ] . Diff erent formulations of the same medication may also infl uence the degree and temporal pattern of absorption and, hence, medication concentrations in the body. TDM uses the quantification of drug concentrations in blood plasma or serum to titrate the dose of individual patients so that a drug concentration associated with highest possible probability of response and tolerability and a low risk of toxicity can be obtained. Moreover, TDM has the possible and widely unexploited potential to improve cost-eff ectiveness of psychopharmacotherapy [ 527 , 660 ] .
For a considerable number of psychopharmacologic compounds, the quantifi cation of the medications' plasma concentration has become clinical routine for dose adjustment. Clear evidence of the benefi ts of TDM has been given for tricyclic antidepressants, a number of old and new antipsychotic drugs and for conventional mood stabilizing drugs [ 51 , 459 , 505 ] . For lithium, TDM has become a standard of care due to its narrow therapeutic range [ 133 , 395 ] .
The benefi ts of TDM regarding the optimization of pharmacotherapy, however, can only be obtained if the method is adequately integrated into the clinical treatment process. Current TDM use in psychiatric care is obviously suboptimal [ 134 , 700 , 742 ] . Similar to other medical disciplines, systematic studies have demonstrated that the inappropiate use of TDM is widespread. Inappropriate TDM testing wastes laboratory resources and also bears the risk that misleading results will adversely infl uence clinical decision making [ 122 ] . A study on the clinical use of TDM for tricyclic antidepressants in psychiatric university hospital settings showed that between 25 and 40 % of the requests for TDM were inappropriate and the interpretation of the results led to about 20 % of inappropriate therapeutic adjustments [ 700 , 742 ] . Other typical errors were absence of steady-state conditions and transcription errors on the request form [ 700, 743 ] . Studies on TDM for antidepressant and mood stabilizing drugs further specifi ed the information on the inappropriate use of TDM [ 420 , 421 ] . Against this background, the TDM group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued best practice guidelines for TDM in psychiatry in 2004 [ 51 ] . These guidelines were widely accepted by many laboratories and practicing clinicians. They have been cited more than 200 times in the literature and were translated into German [ 312 ] and French [ 50 ] . Moreover, they were summarized for depression [ 52 ] . The AGNP-TDM consensus guidelines have also been implemented in recent international guidelines on the treatment of mental diseases [ 582 ] . Since 2004, knowledge on TDM has advanced signifi cantly. New psychotropic medications have been introduced which are also candidates for TDM. The TDM group of the AGNP therefore decided to prepare an updated version of their guidelines.
Objectives of this Consensus Document ▼
This document addresses topics related to the theory and practice of TDM in psychiatry. The fi rst part deals with theoretical aspects of monitoring drug plasma concentrations. The second part defi nes indications for TDM and gives reference drug plasma concentrations for dose optimization. The third part describes the best practice of the process of TDM, which starts with the request and ends with the clinical decision to either continue or change the pre-TDM pharmacotherapy.
Aiming to optimise the practice of TDM the following topics were addressed: ▶ defi nition of indications to utilize TDM in psychiatry ▶ defi nition of graded levels of recommendations to use TDM ▶ defi nition of therapeutic reference ranges ("therapeutic windows") and dose-related reference ranges that laboratories can quote and clinicians can use to guide the psychopharmacotherapy ▶ defi nition of alert levels for laboratories to warn the treating physician when plasma concentrations are considered to be too high and potentially harmful ▶ recommendations and help for interpretative services ▶ recommendations concerning the combination of TDM with pharmacogenetic tests analysed. Extracted data on reference ranges were listed in tables by 7 authors (CH, EH, CG, BR, PR, HK). Results of the literature search and analyses were sent out for review to 20 members of the TDM group with inclusion of a checklist how to extract and analyse the data. An internet based and passwordprotected platform was built up for the reviewers to have access to relevant articles. The reviewers' protocols and commentaries were distributed to all authors of these guidelines. Final decisions on data reported in this document were made during 2 consensus conferences and by e-mail communication. Consensus making also included defi nitions of reference ranges, alert levels and graded levels of recommendations to utilize TDM.
Theoretical Aspects of TDM in Psychiatry ▼ Pharmacokinetics, metabolism and pharmacogenetics of neuropsychiatric drugs
Most psychotropic drugs share a number of pharmacokinetic characteristics ▶ good absorption from the gastrointestinal tract within plasma concentrations reaching a maximum within 1-6 h ▶ highly variable fi rst-pass metabolism (systemic bioavailability ranging 5-90 %) ▶ fast distribution from plasma to the central nervous system with 2-to 40-fold higher levels in brain than in blood ▶ high apparent volume of distribution (about 10-50 L/kg) ▶ low trough plasma concentrations under steady-state (about 0.1-500 ng/mL for psychoactive drugs and up to 20 μg/mL for neurological drugs) ▶ slow elimination from plasma (half-life 12-36 h) mainly by hepatic metabolism ▶ linear pharmacokinetics at therapeutic doses which has the consequence that doubling the daily dose will result in a doubling of the plasma level ▶ low renal excretion with small eff ect of renal insuffi ciency on the plasma concentrations of parent drug and active meta bolites ▶ cytochrome P450 (CYP) and UDP-glucuronosyltranferases as major metabolic enzyme systems There are, however, numerous exceptions. For example, venlafaxine, nefazodone, trazodone, tranylcypromine, moclobemide, quetiapine, rivastigmine and ziprasidone display short (about 2-10 h) elimination half-lives, whereas aripiprazole and fl uoxetine have long elimination half-lives (72 h for aripiprazole and 3-15 days for fl uoxetine, taking into account its active metabolite norfl uoxetine). Amisulpride, milnacipran, memantine, gabapentin, or sulpiride are not or only poorly metabolised in the liver but also mainly excreted renally. Paroxetine exhibits non-linear pharmacokinetics, due to the inhibition of its own metabolism by a metabolite which is irreversibly bound to the enzyme (mechanism based inhibition) resulting in its inactivation [ 69 ] . Many psychotropic drugs are used as racemic compounds, and their enantiomers diff er markedly in their pharmacology, metabolism and pharmacokinetics [ 53 , 605 ] . So far however, methadone, methylphenidate and fl upentixol are at present the only racemic psychotropic compounds for which TDM of the enantiomers has been introduced [ 39 , 189 ] . The active principles of racemic methadone and fl uoxetine are (R)-methadone and cis-(Z)-fl upentixol, respectively. For research projects and other special situations, stereoselective analysis should be considered, e. g., for citalopram, fl uoxetine, reboxetine, venlafaxine, paliperidone or amitriptyline metabolites.
Most psychotropic drugs undergo phase-I metabolism by oxidative (e. g., hydroxylation, dealkylation, oxidation to N-oxides, S-oxidation to sulfoxides or sulfones), reductive (e. g., carbonyl reduction to secondary alcohols) or hydrolytic reactions, dealkylation, oxidation to N-oxides, carbonyl reduction to secondary alcohols or S-oxidation to sulfoxides or sulfones. The phase-I reactions are predominantly catalysed by cytochrome P450 (CYP) enzymes which comprise more than 200 isoenzymes. The most important isoenzymes for psychotropic medications are CYP1A2, CYP2B6, CYP2D6, CYP2C9, CYP2C19 and CYP3A4/5 ( • ▶ Table 1 ) [ 745 -747 ] . In general, phase-I reactions introduce a polar functional group that enables a phase-II conjugation reaction with highly polar molecules such as glucuronic or sulphuric acid. For psychotropic compounds possessing functional groups in the parent compound, glucuronidation of a hydroxyl group (for example oxazepam or lorazepam) or an N-H group (for example olanzapine) may represent the essential metabolic pathway. In addition, tertiary amine groups can be conjugated with the formation of quaternary ammonium glucuronides. Actually, phase II enzymes are poorly characterised with regard to substrate specifi city, and there is much overlap between the isozymes regarding affi nity for substrates [ 143 ] .
Other enzymatic systems may also be involved, such as ketoaldehyde oxidases [ 43 ] , which have been shown to reduce ziprasidone to its dihydro-derivative [ 58 ] or naltrexone to naltrexol [ 92 ] , or MAO-A and MAO-B, which deaminate citalopram stereoselectively to an apparently inactive acidic metabolite [ 562 ] . Drugs are metabolised mainly in the liver and, to a minor degree, in extrahepatic tissues such as the intestinal mucosa or the brain [ 59 , 238 , 444 ] . Inter-and intra-individual diff erences in plasma concentrations of psychotropic drugs (i. e., the pharmacokinetic variability) are caused by diff erent activities of drug-metabolising enzymes. The enzyme activity may decrease with age [ 374 ] and can be modifi ed by renal and hepatic diseases. Gender differences have been reported for psychotropic drugs, but the fi ndings are inconsistent and the clinical relevance is not clear [ 7 -9 , 608 ] . For a number of psychoactive drugs, metabolites actively contribute to the overall clinical eff ect of the parent compound. For this reason, TDM must include the quantifi cation of active metabolites, e. g., in the case of clomipramine (norclomipramine), doxepin (nordoxepin), fl uoxetine (norfl uoxetine) or risperidone (9-hydroxyrisperidone). For drugs like sertraline or clozapine, the clinical relevance of their metabolites norsertraline and norclozapine, respectively, is still a matter of debate. The analysis of pharmacologically inactive metabolites, however, may give useful information on the metabolic state of the patient or on his/her compliance [ 105 , 569 ] . • ▶ Table 2 shows the "normal" ratios of concentrations of metabolites to parent drugs. Calculated ranges contain 68 % of the ratios expected under standard dosages, i. e., ratios within the range of the mean ± 1 SD assuming normal distribution. A ratio above or below the "normal ratio" ( • ▶ Table 2 ) can indicate problems of drug adherence [ 546 ] or metabolic abnormalities due to a genetic variation [ 157 , 159 , 350 , 592 ] or a drug-drug interaction. Spina and coworkers [ 618 ] have shown this for the conversion of 2-hydroxydesipramine to desipramine. With regard to drug-drug interactions, ratios increase if the enzymatic conversion of the parent medication is induced by concurrent psychotropic or non-psychotropic medications or pharmacokinetically relevant activities such as smoking ( • ▶ Table 3 ). Other co-medications and food which inhibit metabolic enzymes may decrease the ratio. • ▶ Table 3 summarizes drugs that are inhibitors or inducers of CYP enzymes and thus may lead to clinically relevant pharmacokinetic drugdrug interactions.
Pharmacogenetic aspects
The clinical importance of pharmacogenetic factors in the pharmacokinetics and pharmacodynamics of psychoptropic drugs is increasingly recognised [ 156 , 199 , 457 ] . Drug-metabolising enzymes, especially CYP isoenzymes, exhibit genetic variability [ 745 -747 ] . When the frequency of a deviation in the alleles is at least 1 % of the population, it is considered a genetic polymorphism. The number of active alleles in a gene determines how much of the enzyme is expressed (phenotype). Poor metabolisers (PM) lack functional alleles. Intermediate metabolisers (IM) are either genetically heterozygous, carrying an active and an inactive allele (or an allele with reduced activity) or have 2 alle-les with reduced activity. Extensive metabolisers (EM) are wildtype with 2 active alleles, and ultra-rapid metabolisers (UM) have an amplifi cation of functional alleles [ 66 ] . Genetic polymorphisms of drug-metabolising enzymes may be clinically important, because unexpected adverse reactions and toxicity may occur in PM due to increased plasma concentrations and non-response may occur in UM due to subtherapeutic plasma concentrations [ 160 ] . Prodrugs are activated by metabolism such as codeine by CYP2D6 to morphine or clopidogrel by CYP2C19 to 2-oxoclopidogrel. PM patients will not be able to produce pharmacologically active metabolites. Other enzyme systems such as UDP-glucuronosyltransferases also display genetic polymorphism [ 155 ] , but their clinical relevance in pharmacopsychiatry is unclear. CYP genotyping methods are becoming more and more available, and guidelines have been published for their use in clinical practice [ 675 ] . The functional signifi cance of many genotypes, Inhibition of enzymes indicated in bold will signifi cantly increase the plasma concentrations of the drug, induction (CYP1A2, CYP3A4) will lead to decreased plasma concentra- This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
however, is unclear. For some enzymes, a genetic polymorphism is not clearly demonstrated despite the fact that they display a wide interindividual variability in their activity. Therefore it may be advantageous to use phenotyping methods with probe drugs such as caff eine for CYP1A2, omeprazole for CYP2C19, dextromethorphan for CYP2D6, or midazolam for CYP3A4/5 [ 403 , 643 ] . Phenotyping measures the metabolic situation of the patient at the moment of the test, and allows to follow its evolution. The measurement, however, may be infl uenced by environmental factors such as smoking or comedications [ 201 , 601 , 749] .
The clear advantage of genotyping is that it represents a "trait marker" and that its result is not infl uenced by environmental factors. It can be carried out in any situation and its result has a lifetime value. Recent investigations indicate that the drug effl ux transporter P-glycoprotein (P-gp) in the intestinal mucosa and blood-brainbarrier is also relevant for the pharmacokinetic variability of psychotropic medications [ 1 ] . This protein, a member of the ATP-cassette binding (ABC) transporter protein family, is encoded by the multidrug resistance gene ( MDR1 ; ABCB1 ). It displays a genetic polymorphism, but as yet, mainly genotyping but not phenotyping (e. g., with digoxin) is more commonly used [ 129 , 183 , 210 , 389 ] . Genetic polymorphism of P-gp may be of the same considerable clinical relevance as has been demonstrated for drug-metabolizing enzymes. For antidepressant drugs that are substrates of P-gp, a genotype dependent association of drug response was found [ 668 , 669 ] . Both plasma concentrations of quetiapine and its clinical eff ectiveness have been shown to depend on the P-gp genotype of patients suff ering from schizophrenia [ 470 ] . With regard to the occurrence of wanted or unwanted clinical eff ects of psychoactive drugs, some fi rst reports suggest the infl uence of the genetic polymorphism of P-gp [ 279 , 560 ] . However, further research is needed to evaluate the clinical relevance of the genetic polymorphisms of drug transporters.
Dose and drug concentration in blood
In most situations that use TDM for dose optimization, drugs are administered in a series of repeated doses to attain a steadystate concentration within a given therapeutic reference range. Steady-state is attained when the rate of medication input equals the rate of medication loss, i. e., approximately after 4 times the elimination half life. With multiple dosing, 94% of the steady state are achieved after 4 and 97% after 5 elimination half-lives. For more than 90 % of all psychoactive medications, such a steady-state is reached within 1 week of maintenance dosing. The dose required to attain a steady-state concentration of a drug in plasma can be calculated if the dosing interval (τ), the clearance (Cl) and the bioavailability (F) for the drug in a particular patient are known. The calculation is based on the direct correlation of the drug dose D e (constant dose per day at steady-state) to its blood concentration c, with the total clearance of the drug (Cl t ) being the correlation coeffi cient:
D e = DxF/τ = c x Cl t
Based on this information it is possible to calculate the dose-related plasma concentration of a drug that may be expected in blood specimens of patients under medication with a given dose [ 285 ] :
For psychoactive medications, such data are available from studies in which drug concentrations were measured in plasma of healthy volunteers or patients treated with fi xed doses. When the clearance is taken as arithmetic mean ± standard deviation from clinical trials of the drug, a dose related reference range can be calculated [ 285 ] .
• ▶ Table 4 lists factors for calculation of dose-related reference ranges for the most relevant psychoactive drugs. Dose-related reference ranges are calculated by multiplying C/D low and C/D high
Defi nition
The "dose-related reference range" reported in the present guidelines is calculated as a concentration range within that a drug concentration is expected according to pharmacokinetic studies in human blood specimens from subjects under medi cation with a given dose of the drug. It contains 68 % of all the drug concentrations determined under normal conditions in the blood of a "normal" patient or subject, "normal" being defi ned by the population in the respective clinical trial. It usually consists of individuals 18-65 years of age without relevant comorbidity, comedication, and genetic abnormalities in drug metabolism. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
by the daily dose. One must be aware, however, that many patients encountered in the clinical context do not fulfi l all the abovementioned conditions.
Drug concentration in blood and brain
The pharmacological activity of a psychotropic drug depends on its availability in the target organ, the brain. However, the latter is separated from the blood by 2 barriers, which have to be crossed by the drug, the blood-brain barrier (BBB) and the blood-cerebrospinal fl uid barrier [ 154 ] . Most psychoactive drugs enter the brain due to their high lipid solubility by passive diff usion and thereby cross the barriers. The BBB is a physical barrier that separates circulating blood and the central nervous system, and it consists of endothelial cells around the capillaries joined together by tight junctions [ 154 ] . It effi ciently restricts the exchange of solutes between the blood and the brain extracellular fl uid. Functionally, it protects the brain against potentially harmful chemicals. As mentioned above, a number of psychoactive drugs, such as risperidone, aripiprazole or venlafaxine are substrates of P-gp [ 180 , 370 , 668 ] . As a consequence, brain to plasma concentration ratios vary widely for psychotropic drugs with similar physicochemical properties. Animal studies found ratios from 0.22 for risperidone [ 29 ] to 34 for fl uphenazine [ 27 ] .
In spite of highly variable ratios of brain to plasma concentrations of the diff erent psychotropic drugs, animal studies have shown that steady-state plasma concentrations of psychoactive drugs correlate well with concentrations in brain, much better than doses. This has been shown for tricyclic antidepressants [ 249 ] , trazodone [ 173 ] , or olanzapine [ 28 ] . Drug concentrations in plasma can therefore be considered as a valid surrogate marker of concentrations in brain.
Drug concentration in blood and target structure occupancy in brain
Positron emission tomography (PET) enables analysis of central nervous receptor occupancy in vivo [ 207 , 274 , 275 ] . Antipsychotic drugs exert most of their therapeutic actions by blockade of dopamine D2-like receptors. Blockade of D2 receptors by antipsychotic drugs reduces the binding of radioactive PET ligands [ 207 , 272 , 275 ] . Using this approach and quantifi cation of the displacement of dopamine receptor radioligands, it has been shown that plasma concentrations of antipsychotic drugs correlate well with receptor occupancy. In accordance with the high variability of drug concentrations in plasma under same doses it was found that receptor occupancy correlates better with plasma concentrations than with daily doses [ 313 ] . Optimal response was seen at 70-80 % receptor occupancy, and 80 % receptor occupancy was defi ned as the threshold for the occurrence of extrapyramidal side eff ects [ 207 , 480 ] . PET was also used to characterize in vivo serotonin transporter occupancy by SSRIs [ 442 , 443 ] . Using a serotonin transporter radioligand, plasma concentrations of citalopram, paroxetine, fl uoxetine and sertraline were shown to correlate well with serotonin transporter occupancy. It was found that at least 80 % occupancy should be attained for optimal clinical outcome [ 442 , 443 ] . PET studies have thus brought about highly relevant information for the determination of optimal plasma concentrations of a considerable number of psychotropic drugs which is reviewed in this special issue by Gründer and co-workers [ 274 ] .
"Therapeutic window" -therapeutic reference range
TDM is based on the assumption that there is a relationship between plasma concentrations and clinical eff ects (therapeutic improvement, side eff ects and adverse eff ects). It also assumes that there is a plasma concentration range of the drug which is characterized by maximal eff ectiveness and maximal safety, the so-called "therapeutic window". Studies on relations between plasma concentration and clinical improvement have supported this concept since the sixties for lithium, tricyclic antidepressants and classical antipsychotic drugs. Systematic reviews and meta-analyses that were based on adequately designed studies led to convincing evidence of a signifi cant relationship between clinical outcomes and plasma concentrations for nortriptyline, imipramine and desipramine which are associated with a high probability of response [ 51 ] . For amitriptyline as a model compound, a meta-analysis of 45 studies has shown that various statistical approaches provided almost identical results [ 672 , 674 ] .
For new antipsychotic drugs like aripiprazole [ 612 ] , olanzapine [ 509 ] or risperidone [ 737 ] relationships between plasma concentration and clinical eff ectiveness have been reported. For the "therapeutic window" there are many synonymous terms like "therapeutic reference range", "therapeutic range", "optimal plasma concentration", "eff ective plasma concentration", "target range", "target concentration", or "orienting therapeutic range", the term used in the fi rst consensus [ 51 ] . The present consensus uses the term "therapeutic reference range" in accordance with the guidelines on TDM for antiepileptic drugs [ 499 ] . The "therapeutic reference range" was defi ned in this consensus guideline for neuropsychiatric drugs as follows:
The therapeutic reference ranges as recommended by the TDM group of the AGNP are given in • ▶ Table 5 . They were evidencebased and derived from the literature by the structured review process described above. For only 15 neuropsychiatric drugs therapeutic reference ranges based on randomized clinical trials were found in the literature. For most drugs, reference ranges were obtained from studies with therapeutically eff ective doses. Therefore, there is a need for further studies to defi ne therapeutic ranges.
The reference ranges listed in • ▶ Table 5 are generally those for the primary indication. A number of drugs, however, are recommended for several indications. For example, antidepressant drugs are also used for the treatment of anxiety states, and antipsychotic drugs are increasingly used to treat mania. Little information is available on optimum plasma concentrations in these situations. Exceptions are carbamazepine, lamotrigine and
Defi nition
The " therapeutic reference ranges " reported in this guideline ( • ▶ Table 5 ) defi ne ranges of medication concentrations which specify a lower limit below which a drug induced therapeutic response is relatively unlikely to occur and an upper limit above which tolerability decreases or above which it is relatively unlikely that therapeutic improvement may be still enhanced. The therapeutic reference range is an orienting, population based range which may not necessarily be applicable to all patients. Individual patients may show optimal therapeutic response under a drug concentration that diff ers from the therapeutic reference range. Ultimately, psycho pharmacotherapy can be best guided by identifi cation of the patient's "individual therapeutic concentration". Plasma concentrations given in mass units can be converted to molar units by multiplication with the conversion factor (CF) nmol/L = ng/mL x CF valproic acid, which are therefore listed twice in • ▶ Table 5 .
Moreover, it should be mentioned that studies are on the way to evaluate therapeutic reference ranges for children or adolescent patients and for elderly patients.
Estimation of the lower limit of the therapeutic reference range
Estimation of a therapeutic reference range (TRR) requires estimation of a lower and an upper limit of drug concentration in plasma. A generally accepted method for calculation of these limits does not exist. Whenever possible the lower limit of a drug's therapeutic range should be based on studies on the relationship between a drug's plasma concentration and clinical eff ectiveness. Below this limit, therapeutic eff ects are not signifi cantly diff erent from placebo. The optimum study design for evaluation of the lower limit of the therapeutic range is a prospective double-blind study where patients are treated with drug doses which lead to a defi ned plasma concentration range of the drug. Such a design was applied by Van der Zwaag and coworkers for patients treated with clozapine [ 678 ] . Patients were titrated to 3 diff erent plasma concentrations of the antipsychotic drug. Signifi cant superiority was found in patients with middle and high plasma concentration compared with low concentrations of clozapine. A similar design was applied for a blood-level study comparing imipramine and mirtazapine [ 98 ] . To conduct such studies, however, is a considerable logistic challenge. Fixed dose studies are therefore preferred for evaluation of the lower limit of the therapeutic reference range [ 672 , 674 ] .
For the estimation of threshold values of the therapeutic reference range, receiver operating characteristic (ROC) analysis has proven helpful [ 289 ] . A ROC plot allows the identifi cation of a cut-off value that separates responders from non-responders and estimates the sensitivity and specifi city of the parameter "medication plasma concentration". The usefulness of the ROC analysis has been demonstrated for a number antipsychotic and antidepressant drugs [ 461 , 505 , 510 , 703 ] .
Estimation of the upper limit of the therapeutic reference range
In the fi rst study on TDM in psychiatry [ 31 ] an U-shaped relationship between plasma concentration and clinical eff ect was reported for nortriptyline. The lack of eff ect at high concentrations was attributed to the mechanism of action of the tricyclic antidepressant drug on monoaminergic neurons. According to actual knowledge, however, it seems more likely that reduced amelioration at high concentrations is due to side eff ects. The upper limit of the therapeutic range is therefore defi ned by the occurrence of side eff ects, also in this guideline. For most side eff ects (type A adverse reactions), it is also assumed that they are a function of dose and drug concentration in the body [ 335 ] . This assumption has been confi rmed for motor side eff ects of antipsychotic drugs [ 536 ] and for unwanted side eff ects of tricyclic antidepressant drugs [ 153 , 282 ] . For paroxetine, a positive correlation was found between drug concentration in plasma and serotonin syndrome symptoms [ 303 ] . When such data are available, it is possible to apply ROC analysis for the calculation of the upper limit of the therapeutic range [ 461 ] . For many psychotropic drugs listed in • ▶ Table 5 , however, valid data on both plasma concentration and the incidence of side eff ects are lacking. Case reports on tolerability problems or intoxications do often not include drug concentration measurements in plasma. Sporadic reports on fatal cases and intoxications are of limited value. Most blood concentrations reported to have caused death are far above drug concentrations that are associated with maximum therapeutic eff ects [ 544 , 622 ] . Post mortem redistribution of medications from or into the blood can lead to dramatic changes in blood levels [ 382 , 518 ] , and the direction of the change does not follow a general rule [ 359 ] . Estimation of an upper threshold level above which tolerability decreases or the risk of intoxication increases is therefore more diffi cult than estimation of the lower threshold level, especially for drugs with a broad therapeutic index like SSRIs.
Estimation and defi nition of a laboratory alert level
As explained above, plasma concentrations with an increased risk of toxicity are normally much higher than the upper threshold levels of the therapeutic reference ranges for most psychotropic drugs shown in • ▶ Table 5 . For the present guidelines, we therefore defi ned an upper plasma concentration limit above which it seems unlikely that therapeutic eff ects may be enhanced and added a "laboratory alert level" which was defi ned as follows:
From population-based to subject-based reference values
All therapeutic reference ranges listed in • ▶ Table 5 are orienting, population-based ranges. The population-derived ranges constitute descriptive statistical values which may not necessarily be applicable to all patients. Individual patients may show the optimum therapeutic response under a drug concentration that diff ers from the therapeutic reference range. Psychopharmacotherapy should therefore try to identify a patient's "individual therapeutic concentration" to guide the treatment [ 61 , 523 ] . For lithium it has been shown that the recommended plasma concentration range depends on whether the patient is in an acute manic episode or needs maintenance therapy [ 593 ] . For clozapine, Gaertner and colleagues [ 232 ] determined optimal plasma concentrations required for stable remission of individual patients under maintenance therapy in a relapse prevention study.
Recommendations for measuring plasma concentrations of psychoactive drugs
The usefulness of TDM varies with the clinical situation and the particular drug involved. In case of suspected non-adherence to medication or intoxications, quantifying plasma concentrations is a generally accepted tool for all drugs and groups of patients. However, it is still a matter of debate if TDM should be imple-
Defi nition
The "laboratory alert levels" reported in this guideline ( • ▶ Table 5 ) indicate drug concentrations above the recommended reference range that causes the laboratory to feedback immediately to the prescribing physician. The alert levels are based on reports on intolerance or intoxications and plasma concentration measurements. In most cases, however, it was arbitrarily defi ned as a plasma concentration that is 2-fold higher than the upper limit of the therapeutic reference range. The laboratory alert should lead to dose reduction when the patient exhibits signs of intolerance or toxicity. When the high drug concentration is well tolerated by the patient and if dose reduction bears the risk of symptom exacerbation, the dose should remain unchanged. The clinical decision, especially in case of unchanged dose needs to be documented in the medical fi le. mented in clinical routine. Based on empirical evidence, 5 levels of recommendation to use TDM were defi ned in the guidelines 2004 for 65 psychotropic drugs. These defi nitions were revised and grading reduced to 4 levels of recommendation, now ranging from "strongly recommended" to "potentially useful" as follows:
According to our literature-based evaluations, TDM was graded as "strongly recommended" for 15 of the 128 surveyed neuropsychiatric compounds, "recommended" for 52 medications, "useful" for 44 drugs and "potentially useful" for 19 drugs ( • ▶ Table 5 ).
TDM is highly recommended for most tricyclic antidepressants . It reduces the risk of intoxications [ 103 , 381, 459 , 510, 525 , 527 , 528 , 530, 718 ] , and for many tricyclic antidepressants, a plasma concentration -clinical eff ectiveness relationship has been shown. For SSRIs, TDM is of little clinical importance in clinical practice [ 6 , 537 , 644 ] . Toxicity of this type of antidepressants is low in comparison to most of the pre-SSRI antidepressants [ 48 , 166 , 314 , 646 , 715 ] . Data from Sweden revealed that TDM of SSRIs is cost-eff ective in elderly patients where it helped to use minimum eff ective doses [ 410 ] . For citalopram a recent observational study revealed that plasma concentrations on day 7 of treatment are predictive for later non-response [ 491 ] . Patients exhibiting citalopram plasma concentrations below 50 ng/mL had a signifi cantly reduced improvement on the Hamilton rating scale for depression. Evidence for a statistically signifi cant relationship between drug concentration and therapeutic outcome is lacking for the tetracyclic antidepressants maprotiline, mianserin and mirtazapine and also for trazodone and reboxetine, the monoamine oxidase inhibitors moclobemide and tranylcypromine. TDM is strongly recommended for the typical antipsychotic drugs haloperidol, perphenazine and fl uphenazine, and for the atypical antipsychotics amisulpride, clozapine, olanzapine, and risperidone ( • ▶ Table 5 ). Overdosing may lead to extrapyramidal side eff ects. In the case of clozapine, there is a strong correlation between clozapine plasma levels and incidence of seizures.
Avoiding overdosing of typical antipsychotic drugs by TDM is for the majority of patients a matter of quality of life rather than safety [ 136 ] . TDM of antipsychotics is also useful when medication is switched from the oral to the depot form, or vice versa. With regard to the mood stabilizing and/or antimanic drugs lithium, valproic acid and carbamazepine, therapeutic reference ranges and toxic levels are well defi ned. Therefore TDM is strongly recommended for these drugs ( • ▶ Table 5 ). For lithium TDM is even the standard of care [ 133 , 170 , 185 , 280 , 395 , 593 , 706 , 721 ] . For its long-term use, plasma concentrations of 0.5-0.8 nmol/L are advised. For an acute treatment with lithium, it may be justifi ed to increase its concentrations up to 1.2 mmol/L. Compounds that have been shown to be eff ective as antidementia drugs are donepezil, rivastigmine, galantamine and memantine. TDM is rarely used for the treatment of dementia, though there is evidence that it can be useful. For donepezil, it has been shown that the patients' improvement was signifi cantly better if their plasma concentrations were above 50 ng/mL as compared to patients that showed lower drug concentrations [ 563 ] .
Most anxiolytic and hypnotic drugs belong to the class of benzodiazepines. Anxiolytic and hypnotic eff ects are rapid. Treatment can therefore be guided by immediate clinical impression rather than by TDM. In case of lack of therapeutic eff ects under usual doses, however, TDM may clarify if non-response was due to drug abuse that has led to tolerance or due to pharmacokinetic abnormalities. For alprazolam, TDM may be useful to suppress panic attacks [ 722 ] .
The opiate agonists methadone, R-methadone (levomethadone), buprenorphine, l-α-acetylmethadol (LAAM) and slowrelease formulations of morphine are used for the treatment of opioid addiction. TDM is indicated for patients treated with methadone or R-methadone. The usefulness of TDM for monitoring treatment with "anti-craving" medications such as acamprosate or naltrexone, employed for the treatment of alcohol use disorders, has recently been reviewed elsewhere [ 99 ] . TDM was recommended to enhance the moderate effi cacy of these drugs. For anticonvulsant drugs , TDM is well established, especially for old drugs which are more toxic than the new ones [ 499 ] .
For antiparkinson drugs , TDM has not been established so far.
For the dopamine agonists, data on reference ranges are scarce. For L-dopa, there is an imperfect correlation between plasma concentrations and short-term clinical response [ 479 ] . Nevertheless, we considered the pharmacologic properties of these neurological drugs ( • ▶ Table 1 , 5 ), since psychiatric patients may receive antiparkinson drugs that possibly interfere with the action of psychotropic medication. For most of these drugs Cmax values are given. Table 6 presents a list of indications for TDM in psychiatry.
Indications for measuring plasma concentrations of psychoactive drugs • ▶
The validity of these indications has to be examined on an individual basis and evaluated for each case individually. Similar to any diagnostic test, TDM should only be requested when there is evidence that the result will provide an answer to a well defi ned question.
For drugs with well defi ned therapeutic reference ranges or with a narrow therapeutic index it makes sense to measure plasma levels for dose titration after initial prescription or after dose change. Even without a specifi c problem, there is suffi cient evidence that TDM has benefi cial eff ects for patients treated with these drugs. This holds true for lithium, tricyclic antidepressants, several antipsychotics or anticonvulsants ( • ▶ Table 5 ). For lithium, TDM is even mandatory for safety reasons.
In case of suspected non-adherence or lack of clinical improvement under recommended doses: TDM is a valid tool for treatment with all drugs considered in these guidelines. Loss of adherence is a major problem of long-term medication [ 10 , 55 , 401 ] . In patients with schizophrenia [ 55 , 351 ] and in patients with unipolar or bipolar disorders non-adherence ranges from 10 to 69 % [ 401 , 439 ] . Methods used to measure adherence include pill counting, examining case-note recordings, interviewing patients or noting the attending physicians' clinical judgement about adherence [ 11 , 355 , 685 , 708 ] . Studies have shown that clinicians cannot reliably predict their patients' adherence [ 104 , 579 ] . TDM is advantageous, since it is an objective method and tells the prescribing physician if the drug is in the body at a concentration that is potentially suffi cient for the expected clinical response. Deviations from the expected doserelated reference range ( • ▶ Table 4 ) indicate if the patient has taken his/her medication, and concomitant determination of metabolites is another approach to clarify if the drug was taken continuously as recommended. For interpretation, however, possible interactions with co-medications exhibiting enzyme inhibiting or inducing properties must be considered ( • ▶ Table 3 ).
Reis and coworkers [ 546 , 547 ] analysed the compliance of patients who were treated with sertraline by repeated determination of serum drug concentrations of the parent compound and of the metabolite. Variations of the ratios of concentrations of norsertraline to sertraline were highly indicative for hidden and partial non-adherence. To be able to use this approach, these guidelines were supplemented with data on ratios of concentrations for 32 psychoactive drugs ( • ▶ 1 ) such as clozapine [ 81 , 676 ] , duloxetine [ 222 ] or olanzapine [ 749 ] . It should also be mentioned that many pharmacokinetic drug-drug interactions have been found by TDM either by chance or by retrospective analysis of TDM data bases [ 112 , 537 ] .
In pharmacovigilance programs , the safety of drug use is supervised under naturalistic conditions [ 271 , 285 ] . In case of observed adverse events, measurement of plasma concentrations is most helpful for clarifi cation [ 335 ] . Relapse prevention is a major goal of maintenance treatment. Reduction of relapse rates by TDM is highly cost-eff ective, as relapses can lead to hospitalization [ 377 ] . In schizophrenic patients, it has been shown that fl uctuations of clozapine plasma concentrations are predictive for relapses [ 232 , 670 ] and rehospitalizations [ 627 ] . In these patients, TDM may help reduce the risk of relapse or recurrence by increasing adherence to the medication. One day in the hospital is 4-16 times more expensive than a single drug concentration measurement in the laboratory.
In patients exhibiting genetic peculiarities of drug metabolizing enzymes, doses must be adapted. Kirchheiner and coworkers [ 362 , 365 ] which extent the plasma concentration may be changed in the individual patient [ 496 , 497 , 625 ] .
For special groups of patients , such as pregnant or breastfeeding patients, children or adolescent patients [ 22 , 373 , 194 ] , individuals with intellectual disabilities [ 158 , 300 ] , or elderly patients, especially patients aged above 75 years [ 374 ] , TDM is highly recommended. Any psychopharmacologic therapy of pregnant or breastfeeding women should assure that the plasma concentration of the drug is in the therapeutic reference range to minimize the risk of relapse on the mother's side and, at the same time, to minimize risks associated with drug exposure of the fetus or the child [ 169 , 174 ] . Renal clearance and the activity of the CYP isoenzymes 3A4, 2D6 and 2C9, and uridine 5′-diphosphate glucuronosyltransferase are increased during pregnancy, whereas activities of CYP1A2 and 2C19 decrease [ 21 ] . TDM in pregnant women and/or mothers should be carried out at least once per trimester and within 24 h after delivery [ 65 ] . Many psychoactive drugs are not approved for use in children or adolescents [ 248 ] . Pharmacokinetics and pharmacodynamics change during development [ 194 , 438 , 514 , 516 ] . In adolescents suff ering from psychotic disorders, comorbid drug abuse is very common, and compliance with an antipsychotic treatment is generally marginal [ 318 ] . Therefore, TDM is recommended in these patients. To raise data on the eff ectiveness and tolerability of psychoactive drugs under every day conditions, a TDM network was established for child and adolescent patients [see http://www.tdm-kjp.de/eng/contact.html].
In elderly patients , who frequently are hypersensitive to medication, TDM is helpful to distinguish between pharmacokinetic and pharmacodynamic factors when adverse eff ects occur [ 666 ] .
Ageing involves progressive impairments of the functional reserve of multiple organs [ 407 ] , especially renal excretion, and body composition changes signifi cantly [ 361 , 374 ] . Hepatic clearance can be reduced by up to 30 %. Phase I reactions are more likely to be impaired than phase II reactions. On the other hand, there are no age-dependent changes in CYP isoenzyme activity [ 374 ] . Age-related changes in physiologic and pharmacokinetic functions as well as the comorbidity and polypharmacy complicate pharmacotherapy in the elderly [ 125 ] . Therefore, TDM should be used for these patients to improve safety and tolerability of psychopharmacotherapy.
In individuals with intellectual disabilities , new generation antipsychotic drugs are frequently used. Recently published guidelines recommend TDM for these patients, at least when treated with risperidone or olanzapine [ 158 ] . For ethical and legal reasons, patients with intellectual disabilities are excluded from clinical trials. On the other hand, many of these patients need medication. In these individuals, it may be diffi cult to differentiate between morbogenic and pharmacogenic reasons for symptom aggravation. Though evidence is poor, TDM is recommended to guide the pharmacotherapy of these patients [ 158 ] .
In forensic psychiatry the primary aim of pharmacotherapy, consisting mostly antipsychotic drugs, is reduction of dangerous behaviour [ 458 , 462 ] . To consistently reduce the risk of violence and aggression, adherence to the prescribed medication is essential [ 658 ] . Therefore, TDM is recommended for this group of psychiatric patients. It is, however, not clear if eff ective plasma concentrations are identical in forensic and general psychiatry patients. Castberg and Spigset [ 113 ] analyzed data obtained by survey in a high security forensic unit and found higher doses in forensic patients than in a control group. The dose related plasma concentrations were signifi cantly lower for olanzapine but higher for quetiapine in the forensic patients than in the control group.
The indication " problem occurring after switching from an original preparation to a generic form (and vice versa) " is still under-investigated and data are scarce [ 124 , 139 ] .
Another potential indication for TDM not listed in • ▶ Table 6 is the increasing availability of counterfeit drugs on the internet [ 599 ] . WHO launched a program in 2006 to combat this illegal industry. There are no data published on this type of market concerning psychotropic drugs, but patients may be co-medicated (mostly auto-medication) with other drugs obtained from this source. The counterfeit medications may not comply with purity and dosage standards and therefore increase the risk for interactions.
Practical Aspects for TDM in Psychiatry ▼
Essential for an eff ective TDM service is the availability of appropriate analytical methods that produce results within a reasonable time, i. e., 48 h, and advice from someone who understands pharmacokinetics and therapeutics [ 184 ] . As shown in • ▶ Fig. 1 , the TDM process starts with the request and ends with the fi nal decision about how to adjust a given patient's therapeutic regimen by the health care professional.
Request for plasma concentration quantifi cation
As mentioned above, TDM should only be requested when there is evidence that the result will provide an answer to a specifi c question. If it is not clear what the question is, the answer is of little value. Typical indications are listed in • ▶ Table 6 . A single measurement is often insuffi cient for problem solving. For example, a series of measurements may be required at appropriate intervals to clarify if a low plasma concentration is either due to poor compliance, reduced bioavailability or abnormally rapid elimination. Table 6 Typical indications for measuring plasma concentrations of medications in psychiatry.
-Dose optimization after initial prescription or after dose change -Drugs, for which TDM is mandatory for safety reasons (e. g., lithium) -Suspected complete or partial non-adherence (non-compliance) to medication -Lack of clinical improvement under recommended doses -Adverse eff ects and clinical improvement under recommended doses -Combination treatment with a drug known for its interaction potential or suspected drug interaction -TDM in pharmacovigilance programs -Relapse prevention under maintenance treatment -Recurrence under adequate doses -Presence of a genetic particularity concerning drug metabolism (genetic defi ciency, gene multiplication) -Pregnant or breast feeding patient -Children and adolescent patient -Elderly patient ( > 65 y) -Individuals with intellectual disabilities -Patients with pharmacokinetically relevant comorbidities (hepatic or renal insuffi ciency, cardiovascular disease) -Forensic patient -Problems occurring after switching from an original preparation to a generic form (and vice versa) Fig. 1 Schematic overview of the TDM process as a guide for psychopharmacotherapy. Routine TDM is primarily applied to drugs with a narrow therapeutic index and a well-defi ned therapeutic reference range. However, TDM is useful for any psychotropic drug when addressing special therapeutic problems such as "therapy refractoriness" or side eff ects under recommended dosage.
Routine monitoring Specific problem

Blood sample collection, storage and shipment
Steady-state at the time of minimal drug concentration (trough level)
Dose titration
Maintenance therapy for relapse prevention Insufficient response, improvement and side effects at therapeutic doses, potential drug interaction or other problems
Laboratory measurement
Use of validated method (linearity, accuracy, precision, sensitivity, specificity) Internal and external quality controls
Communication of results
Concentration of drug (and metabolite), unit, reference range Interpretation Fig. 2 ) which is essential for eff ective drug concentration measurements and an adequate interpretation of the results [ 501 , 635 ] . The form should contain the patient name or code, demographic data, diagnosis, medication, reason for the request, the commercial and the generic name of the drug and its dose, the galenic formulation, the time of the last change of the dose, time of blood withdrawal. A brief comment on the clinical situation should be given for interpretation of the results. We recommend to use objective symptom rating, e. g., application of the clinical global impression (CGI) scale [ 283 ] , to measure severity of illness and therapeutic improvement. The summary form of the UKU scale is useful to evaluate the occurrence and severity of side eff ects [ 402 ] . However, documented feedback to questionnaires indicates that clinicians often do NOT want to put that much information on the form. Moreover, the fi lled-in information is often not accurate. As an alternative, feedback by phone may be off ered for interested physicians. When interpretation of the results is requested from the laboratory, it is absolutely necessary to fi ll out the request forms adequately and completely. Thereby computerized ordering of TDM has advantages. It is inexpensive and it guides the ordering physician to give the relevant information required for interpretation in a comfortable way. Computerized ordering, however, is still not widely used. But eff ective packages are on the way to become available (e. g., www.konbest.de).
Clinical decision making
Further supervision of pharmacotherapy
Blood sample collection
Generally, TDM is carried out in plasma or serum samples. The analysis of whole blood, which is long established for immunosuppressant drugs by using immunoassays [ 693 ] , has been abandoned for TDM in psychiatry. There is no consensus whether plasma or serum should be preferred. Defi nite experimental data are still lacking which clearly demonstrate diff erences in the drug concentrations using either plasma or serum. The few available comparisons indicate that values obtained from serum or plasma can be used interchangeably [ 308 ] . Most psychoactive drugs are intensively bound to blood cells of plasma proteins. Concentrations of neuropsychiatric drugs reported in this guideline refer to the total drug fraction in accordance with the literature. For imipramine, it has been shown that the drug is rapidly and almost totally cleared by the brain through a single passage in the microvasculature [ 555 ] . The extraction was not signifi cantly aff ected in the presence of albumin, lipoproteins or erythrocytes. For nortriptyline, statistical relationships between free levels of drug and clinical response were found to be insignifi cant [ 506 ] . Therefore it seems likely that the clinical response depends on the total drug fraction. Analysis of psychotropic medications in other materials such as urine, spinal fl uid, tears, hairs or maternal milk have not been introduced for TDM purposes, and no validated data are available which deal with therapeutic concentrations. Saliva off ers the advantage of non-invasive collection [ 20 , 25 , 356 ] . However, the drug concentration in saliva corresponds to the free (i. e., nonprotein-bound) fraction of the drug in blood -which is for most psychopharmacologic medications only 10 % or less of the total concentration. Thus detection problems may occur when using saliva instead of blood plasma or serum. In any case, more data will have to be obtained for saliva as a matrix for measurement of drug concentrations. With few exceptions, TDM relies on trough steady-state plasma concentrations. Blood should therefore be collected after at least 4 drug elimination half-lives after the start of or a change in dosage and during the terminal ß-elimination phase. For most psychotropic drugs, elimination half-lives vary between 12 and 36 h ( • ▶ Table 5 ). Notable exceptions are quetiapine, trazodone, or venlafaxine, which display elimination half-lives around 6 h. Fluoxetine and aripiprazole have longer elimination half-lives. In clinical practice, the appropriate sampling time for most psychoactive drugs is one week after stable daily dosing and immediately before ingestion of the morning dose, which usually is 12-16 h (or 24 h if the drug is given once daily in the morning) after the last medication. If, for logistics reasons, blood can only be collected late in the morning, the patient should not be medicated before blood withdrawal. In an outpatient setting it is important to indicate exactly the time of administration of the last dose for interpretation. Trough levels can then be extrapolated by pharmacokinetic modelling. In patients treated with a depot preparation of an antipsychotic drug, blood should be sampled immediately before the next injection. Formulations of antipsychotic drugs such as haloperidol decanoate or risperidone microspheres are characterised by a slow absorption after intramuscular administration. Maximum plasma concentration of fi rst generation depot antipsychotics are reached after 1-14 days after injection, and the apparent elimination half-life is 2-3 weeks [ 647 ] . Similar properties exhibits the newly introduced paliperidone palmitate [ 131 ] . For risperidone microspheres the mean time to peak concentrations is 4 weeks and its plasma half life 4-6 days [ 647 ] . For other drugs delivered in extended or retarded release formulations like paliperidone [ 70 ] or quetiapine [ 212 ] , special attention has to be given to the time of drug intake for correct interpretation (see • ▶ Table 5 ). In these formulations, the time of maximum plasma concentration is delayed but the elimination half-life remains essentially unchanged. The long acting olanzapine pamoate is a new depot formulation [ 399 ] . The salt slowly releases olanzapine from the injection site into the muscle tissue. However, it dissolves rapidly when it is in contact with blood or plasma. The latter results in high plasma concentrations and may lead to marked sedation and delirium, the so called post-injection syndrome [ 399 , 647 ] . Considering this special problem it could be useful to control plasma concentrations of olanzapine shortly (i. e., about 2 h) after the i. m. injection to monitor if plasma concentrations increase. This approach, however, relies on the rapid quantifi cation of olanzapine. TDM may of course be carried at any time after drug ingestion if unexpected side eff ects are observed. It is not necessary to measure trough levels, but the dosing schedule should be reported for interpretation.
Storage and shipment of blood samples
When samples must be stored and sent frozen, it is required to prepare serum or plasma before freezing, since it is not possible to prepare serum or plasma from frozen blood. With few exceptions, serum or plasma samples can be stored in the dark (at 4 ℃) for at least 24 h, and most drug samples can be sent without freezing [ 305 ] . Exceptions are light and/or oxygen sensitive substances. For the determination of bupriopion or methylphenidate, however, serum samples must be frozen or extracted and stabilized immediately after blood withdrawal and centrifugation (see • ▶ Table 5 ). Olanzapine must be stored frozen (̶ 20 ℃) if not analysed within 72 h [ 305 ] . The laboratory should give instructions on its web site or the request form how This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
to collect (plasma volume, labelling of the samples), store and mail the sample.
Laboratory measurements
Selective and sensitive analytical methods for the quantitative evaluation of drugs and their metabolites (analytes) are essential for the successful conduct of TDM. Methods must be validated which includes all of the procedures that demonstrate that a particular method used for quantitative measurement of analytes in a given biological matrix is reliable and reproducible for the intended use. The fundamental parameters for this validation include (1) accuracy, (2) precision, (3) selectivity, (4) sensitivity, (5) reproducibility and (6) stability. Validation involves documenting, through the use of specifi c laboratory investigations, that the performance characteristics of the method are suitable and reliable for the intended analytical applications.
The acceptability of analytical data corresponds directly to the criteria used to validate the method [ 114 , 219 ] .
For psychoactive drugs, chromatographic techniques (gas chromatography (GC), and high-performance liquid chromatography (HPLC), in combination with suitable detection methods, are preferred [ 186 ] . They are suffi ciently precise, accurate and robust and can be adapted to the analysis of a huge number of drugs. A disadvantage is the need for sample preparation before chromatographic separation and hence a limited sample throughput. Throughput can be enhanced by automated sample preparation prior to GC or HPLC. Some laboratories have introduced HPLC with column switching which allows direct injection of plasma or serum into the HPLC system. Such procedures are available for a number of antidepressant [ 269 , 292 -294 , 297 , 298 , 702 , 710 ] and antipsychotic drugs [ 368 , 369 , 571 -573 , 709 -712 ] . Another high-throughput chromatographic method is liquid chromatography coupled with mass spectroscopy (LC-MS) especially tandem MS (LC-MS/MS). LC/MSMS methods can be applied to almost any psychotropic drug including metabolites [ 577 ] . They are most sensitive and selective and can be used without time-consuming sample preparation. Many compounds can be analysed simultaneously. An excellent example is the LC-MS/MS method described by Kirchherr Table 3 . Any ratio outside the reported "normal" range should be considered as a signal pointing to individual abnormalities due to a drug-drug-interaction, gene polymorphism, altered liver function, non-adherence or drug intake few hours before blood withdrawal.
The assay of enantiomers of chiral compounds requires either stereoselective derivatisation of the drugs prior to their quantifi cation, or their separation by chiral chromatographic GC or HPLC columns. LC-MS/MS may be the method of choice. As an example, the TDM of the enantiomers of methadone using a classical detection method such as fl uorescence or ultraviolet light absorption is often jeopardized by comedication or by coconsumption drugs of abuse. These problems may be circumvented by use of a mass detector, preferably a tandem mass spectrometer.
Within the therapeutic reference range, intraday-and interday precision should not exceed 15 % (coeffi cient of variation) and accuracy should not deviate more than 15 % from the nominal value [ 114 , 219 ] .
To ensure quality and reliability of plasma concentrations assays, internal and external quality control procedures are mandatory. Samples must contain suitable internal standards, and each series of samples must include internal control samples. If standards are not available commercially, they should be prepared by personnel other than those performing the assays and by separate weighing of reference material. Reporting of results requires that the results of the quality controls are within the expected range. If quality controls are outside the expected range, the reason underlying the outlier needs to be clarifi ed and documented.
The laboratory has to participate in an external quality assessment scheme , although this is not a legal requirement in all countries. For neuropsychiatric drugs, the fi rst external quality program was introduced by Cardiff Bioanalytical Services Ltd in 1972 [ 720 ] . It has currently 450 participants from 36 countries (www.heathcontrol.com). Instand e. V. (www.instanddev.de/ ringversuche/) is another recommended provider of external control, the external quality control scheme was recently expanded to multiple psychoactive drugs samples. Moreover, reference materials are also available from forensic chemistry (http://www.pts-gtfch.de/).
Communication of results
The concentration of the psychoactive drug as well as that of active metabolites contributing to the therapeutic action should be reported with reference ranges ( • ▶ treating physician is required when the laboratory measures drug concentrations above the "laboratory alert level" which was newly defi ned (see above) in the present consensus guidelines ( • ▶ Table 5 ).
Interpretation of results
We recommend that interpretation and pharmacologic advice are provided with every report. Expert interpretation of a drug concentration measurement and the adequate use of the information are essential to ensure the full clinical benefi t of TDM.
Reporting of results with inclusion of dose recommendations and other comments must be guided by the best available evidence. Expert knowledge may be necessary to calculate dose corrections or to analyse drug-drug interactions. It is therefore advantageous for the clinician to choose a laboratory that off ers this service. Otherwise, the treating physician, a clinical pharmacologist or a trained expert of the clinic has to interpret the results. Access to specialist advice is also necessary if TDM results suggest that genotyping may be advisable [ 335 ] .
Diagnosis and drug dose are important information for interpretation, since they permit a judgement on whether a result is plausible or not. Moreover, it must be controlled if blood samples were collected under recommended conditions, especially when the plasma concentration is unexpectedly high in an outpatient. When the drug was taken a few hours before blood sampling the drug concentration can be several-fold higher than the trough level.
For the interpretation of the results, it should not only be considered whether the plasma concentration of the drug is within the "therapeutic reference range" ( • ▶ Table 5 ). It must also be considered if the drug plasma concentration is consistent with the dose ( • ▶ Table 4 ). A plasma concentration may be outside the therapeutic reference range, just because a low or high dose was taken. In addition, it is wise to take into account the level of evidence underlying the "therapeutic reference range" of the particular drug ( • ▶ Table 4 ) but outside the "therapeutic reference range" of • ▶ Table 5 which was established for the indication of depression.
A laboratory may recommend that an additional sample should be taken after a certain period, because in cases with unusually low or high plasma concentrations, repeated measurements may help to decide whether the patient's adherence is inconstant (irregular intake of the drug) or whether the patient is an abnormal metabolizer.
Since the interpretation of TDM results relies on complex quantitative relationships, training in clinical psychopharmacology and pharmacokinetics and the application of TDM is essential. Regular conferences with discussion of the interpretation of real cases are most helpful for learning. It is also recommended that junior psychiatrists interpret the results under supervision of an expert.
Clinical decision making
A TDM result is a guide to proper dosing of the individual patient.
The physician has to be aware that, under optimal conditions, reporting of results with inclusion of dose recommendations and other comments by the laboratory is guided by the best available evidence [ 310 ] . The laboratory, however, has only a restricted knowledge of the clinical situation. On the other hand, most treating physicians have limited pharmacokinetic knowledge. Therefore it is essential to be aware that optimal TDM is an interdisciplinary task that requires close communication between laboratory and clinical experts.
If the plasma concentration of the drug is within the therapeutic reference range, an adaptation of the dose is, of course only recommended when clinical reasons, such as adverse eff ects or non-response clearly justify such a decision. Evidently, the treating physician has to decide whether the treatment strategy is to be changed or not. On the other hand, when the advice given on the TDM report is not followed, the reason for this course of action must be substantiated to allow evaluation of the treating physician's decision should the patient come to harm. appears to be a highly reliable predictor of later non-response [ 358 ] . For dose titration with antidepressant and antipsychotic drugs we therefore recommend to include symptom rating by the treating physician [ 138 ] at baseline and at week 2 in addition to drug concentration measurements. • ▶ Fig. 3 summarizes the above recommendations in a fl ow chart. When further plasma concentration measurements are recommended after a modifi cation of the dose or after prescription of a comedication that is known to inhibit or enhance the metabolism of the drug to be measured, the next TDM should be delayed until steady-state conditions are reached again. For this, the terminal elimination half-life of the drug has to be considered ( • ▶ Table 5 ).
Pharmacogenetic tests in addition to TDM
Concentrations outside the reference range may be due to gene polymorphisms that give rise to slow/rapid metabolizers. As a consequence, the laboratory may also suggest that a pharmacogenetic test should be carried out [ 14 , 144 , 158 , 193 , 335 , 362 , 365 , 377 , 623 , 624 , 675 ] . Genotyping, however, is not available in all TDM laboratories, and we recommend consultation of speciali zed laboratories for interpretation of the results.
Situations and cases where pharmacogenetic tests could advantageously be combined with TDM are explained in more detail by Jaquenoud Sirot and coworkers [ 335 ] . Some of the most important indications for the combination of genotyping with TDM are the following: ▶ the patient is treated with a substrate the metabolism of which shows a wide interindividual variability; ▶ a drug is characterized by a small therapeutic index: risk of toxicity in the case of a genetically impaired metabolism, or on the other hand, risk of non-response due to an ultrarapid metabolism and the inability to reach therapeutic drug levels; ▶ the patient presents unusual plasma concentrations of the drug or its metabolite(s) and genetic factors are suspected to be responsible; ▶ the patient suff ers from a chronic illness, which requires lifelong treatment. In a patient who is genotyped as a PM or UM, the medication should not automatically be replaced by another as suggested by some authors, but the dose can often be adapted, using clinical judgement and TDM.
Conclusions and Perspectives ▼
The choice of pharmacologic treatment should always take into account the clinical presentation of the patient and consider psychopathology and drug history. TDM is, if used appropriately, a valid tool for optimising pharmacotherapy. During the past decades, knowledge on the metabolic fate and actions of psychotropic drugs in the human body has markedly advanced. Pharmacogenetic and environmental factors have been identifi ed and summarized in the fi rst part of this review. The present updated AGNP guidelines describe the best practice of TDM in psychiatry in order to promote the appropriate use of TDM. Although a considerable body of data for plasma concentrations of psychotropic drugs has been accumulated and although our knowledge about the quantitative relationship between plasma concentration and therapeutic response has improved, there is still a need to conduct further controlled and randomised concentration-response studies to improve the quality of data on therapeutic reference ranges. We also recommend inclusion of pharmacokinetic measurements during phase III and IV studies. Product information should be supplemented with TDM related data to enhance the therapeutic eff ectiveness of psychoactive drugs. Analyses of German [ 671 ] and French [ 568 ] summaries of product characteristics (SPC) revealed that many SPC do not contain TDM related information in spite of available valid clinical-scientifi c evidence. Another need for research is to study cost-eff ectiveness of TDM when the method is used in an appropriate way. Polypharmacy is very common in psychiatry while essentially all TDM recommendations are based on single-medication trials. Thus, the effi cacy of drug combinations constitutes a severely under-investigated area of TDM. Finally, one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data so that, ultimately, the patient can profi t from such a joint eff ort. [ 311 ] ). Clinical decision making has to consider the clinical improvement, the duration of treatment, and steady-state concentration of the drug in plasma or serum. The steady-state is reached by 94 % after 4 elimination half-lives of the drug or active metabolites (see • ▶ Table 5 ).
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